Lung cancer symptoms usually develop as the condition progresses, there tends to be no indications in the early stages. But when they do become apparent, one of the signs can be found in your phlegm. You should make sure to see your GP straight away if this happens.
Oncimmune PLC (LON:ONC) is a leading early cancer detection company. Our patented autoantibody assay technology can detect autoantibodies produced in response to cancer up to 4 years before symptomatic presentation of the disease
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has been awarded the Queen’s Award for Enterprise 2022 in the innovation category, endorsing Oncimmune as a leading developer of applied immunodiagnostics for
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its unaudited interim results for the six months ended 30 November 2021. Financial highlights · Recognised revenue for the period was £1.43M (H1 2020: £1.83M) was
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has today announced it has signed a further commercial contract under its existing master services agreement with a top five global pharmaceutical company, profiling over 350 chronic idiopathic
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication of a paper entitled: “Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection” 1 arising from the research collaboration between Oncimmune and Cedars-Sinai Medical Center
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that the Company has signed further commercial contracts within its ImmunoINSIGHTS pharma services business. MSA and Commercial Contract Signed with Leading Global Pharmaceutical Company Following
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today provided an update on commercial activity within its ImmunoINSIGHTS pharma services business. As we highlighted in the full year results announcement released on 2 November 2021, the
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2021 on Tuesday, 2 November 2021. Analyst and investor presentations Dr Adam M Hill,
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The
Oncimmune Holdings plc (LON:ONC) drew attention to the pre-publication of new research demonstrating how the use of its EarlyCDT-Lung Test, for diagnosing early stage lung cancer, has been shown to reduce mortality when used as part
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the pre-publication of the three-year follow-up data for the Early detection of Cancer of the Lung Scotland trial in medRxiv titled ‘Targeted screening for lung
Oncimmune Holdings plc (LON:ONC) announced a new contract with the Dana-Farber Cancer Institute (Harvard Medical School affiliate based in Boston, US) whereby the latter will utilise Oncimmune’s proprietary SeroTagTM ‘biomarker discover engine’ to identify predictive patient responses
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.